(AOF) – NFL Biosciences announces that it has obtained funding for a total of 1.7 million euros, granted by Bpifrance and funded by the government as part of the Future Investments Program. This biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, and in particular for smoking cessation, announces that as a result its cash horizon “extends now until the end of the third quarter of 2024” after the success of its capital increase of approximately 3 million euros at the end of January.
“We have the appropriate resources to reach the key validation milestones of our two main clinical programs on NFL-101 in the 3rd and 4th quarters of 2023, and to advance in the development of NFL-301”, specifies Ignacio Faus, Chief Executive Officer.
© AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of error and defects, even hidden ones, nor the exhaustive nature or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
